# Ilaris NIS in Korea

> **NCT06838143** · — · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 25 (estimated)

## Conditions studied

- Hereditary Periodic Fever Syndromes
- Cryopyrin-associated Periodic Syndromes (CAPS)
- Colchicine Resistance Familial Mediterranean Fever (crFMF)
- TNF Receptor Associated Periodic Syndrome (TRAPS)
- Hyper-IgD Syndrome / Mevalonate Kinase Deficiency (HIDS/MKD)
- Systemic Juvenile Idiopathic Arthritis (sJIA)

## Interventions

- **BIOLOGICAL:** Ilaris

## Key facts

- **NCT ID:** NCT06838143
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-29
- **Primary completion:** 2028-09-30
- **Final completion:** 2028-09-30
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06838143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06838143, "Ilaris NIS in Korea". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06838143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*